A pharmacovigilance analysis of post-marketing safety of durvalumab
Abstract Durvalumab has demonstrated significant efficacy in several types of malignancies, while large-scale real-world safety studies remain limited. This study aimed to systematically evaluate the safety of durvalumab through data mining of the U.S. Food and Drug Administration Adverse Event Repo...
Saved in:
| Main Authors: | An-Ju Tan, Wan-Ying Liu, Jun-Li Lu, Qing-Ying Tan, Yu Yan, Dun-Chang Mo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-01583-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Post-marketing safety concerns with dolutegravir: a pharmacovigilance study based on the FDA adverse event reporting system database
by: Juan Su, et al.
Published: (2025-07-01) -
Evaluating Triptan Safety in Pediatric Migraine Management: A Comprehensive Pharmacovigilance Analysis
by: Chen J, et al.
Published: (2025-06-01) -
A real-world pharmacovigilance study of lorazepam based on the FDA adverse event reporting system database
by: Chunyue Fang, et al.
Published: (2025-06-01) -
The real-world safety of Nivolumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yutong Wu, et al.
Published: (2025-05-01) -
Adverse drug reaction to tremelimumab and durvalumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database
by: Wei Fan Sui, et al.
Published: (2025-08-01)